Latest News
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical trial of RBS2418, its oral inhibitor of ENPP1, at the...
Lilly to pay Q4 dividend of USD1.73
27 October 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that its board of directors has declared a dividend of USD1.73 per share of common stock for the fourth quarter of 2026.This amount is unchanged from the...
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
27 October 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) uni...
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
27 October 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Monday that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its ifetroban product candidate as ...
Innovent Biologics' sintilimab new indication application accepted for review by NMPA
26 October 2026 - China-based biopharmaceutical company Innovent Biologics (HKEX: 01801) said on Monday that the China National Medical Products Administration (NMPA) has accepted for review a new indication application for sintilimab in combination ...